Further, Humbert et al. have reported the therapeutic significance of 18F-FDG-PET in the early assessment of anti-PD-1 immunotherapy (pembrolizumab and nivolumab) in patients (n = 50) with NSCLC [36], which was evaluated according to three points—at baseline, and after 7 weeks and 3 months of treatment. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.